Text Size

Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00346775
First received: June 28, 2006
Last updated: August 17, 2006
Last verified: August 2006
History of Changes
  Purpose

The objective of this cross-over study is to validate the Preference Module of the EARNS-Q in adult subjects (>=18 years of age) with Seasonal Allergic Rhinitis (SAR) taking beclomethasone dipropionate and beclomethasone dipropionate and flunisolide.


Condition Intervention Phase
Seasonal Allergic Rhinitis
 Drug: Beclomethasone dipropionate
Drug: Flunisolide
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects With Seasonal Allergic Rhinitis During a Three-Week Cross-Over Study

Resource links provided by NLM:

MedlinePlus related topics: Hay Fever
U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • No primary efficacy endpoint - this study concerns the validation of EARNS-Q.

Secondary Outcome Measures:
  • Patient preference with nasal sprays
  • mean rTNSS (reflective total nasal symptom scores) over the 2-week treatment period
  • correlation with other measures of preference using TSQM (Treatment Satisfaction Questionnaire for Medication)

Estimated Enrollment: 90
Study Start Date: March 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Seasonal allergic rhinitis.
  • Nasal allergy symptoms during the spring allergy season.

Exclusion Criteria:

  • Prior use of beclomethasone dipropionate or flunisolide.
  • Significant concomitant medical conditions.
  • Use of corticosteroids.
  • Use of allergy and other identified medications during the study.
  • Current tobacco use or tobacco use within the past year.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00346775

Locations
United States, California
GSK Clinical Trials Call Center
Fresno, California, United States, 93720
GSK Clinical Trials Call Center
Roseville, California, United States, 95678
GSK Clinical Trials Call Center
San Francisco, California, United States, 94102
GSK Clinical Trials Call Center
San Francisco, California, United States, 94104
GSK Clinical Trials Call Center
San Jose, California, United States, 95128
GSK Clinical Trials Call Center
San Jose, California, United States, 95117
GSK Clinical Trials Call Center
Walnut Creek, California, United States, 94598
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trial, M.D. GlaxoSmithKline
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00346775     History of Changes
Other Study ID Numbers: FFR105693
Study First Received: June 28, 2006
Last Updated: August 17, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Seasonal allergic rhinitis
allergic rhinitis
nasal spray questionnaire
nasal spray
questionnaire

Additional relevant MeSH terms:
Rhinitis, Allergic, Seasonal
Rhinitis
Nose Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Otorhinolaryngologic Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Respiratory Tract Infections
Flunisolide
 Beclomethasone
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on June 17, 2013